474 related articles for article (PubMed ID: 26673249)
21. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
Eun JR; Lee HJ; Kim TN; Lee KS
J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
[TBL] [Abstract][Full Text] [Related]
22. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
23. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
[No Abstract] [Full Text] [Related]
24. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation.
Jiang L; Yan L; Wen T; Li B; Zhao J; Yang J; Xu M; Wang W
Transplant Proc; 2013; 45(6):2326-30. PubMed ID: 23953544
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Singal AK; Fontana RJ
Aliment Pharmacol Ther; 2012 Mar; 35(6):674-89. PubMed ID: 22257108
[TBL] [Abstract][Full Text] [Related]
27. Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment.
Joo MK; Yeon JE; Kim JH; Jung YK; Lee SJ; Kim JH; Yim HJ; Byun KS; Park JJ; Kim JS; Bak YT
Scand J Gastroenterol; 2008; 43(12):1514-21. PubMed ID: 18663665
[TBL] [Abstract][Full Text] [Related]
28. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
29. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Lim SG; Mohammed R; Yuen MF; Kao JH
J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
[TBL] [Abstract][Full Text] [Related]
31. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
[TBL] [Abstract][Full Text] [Related]
33. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
Liu K; Choi J; Le A; Yip TC; Wong VW; Chan SL; Chan HL; Nguyen MH; Lim YS; Wong GL
Aliment Pharmacol Ther; 2019 Nov; 50(9):1037-1048. PubMed ID: 31524304
[TBL] [Abstract][Full Text] [Related]
34. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
35. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
Kim JH; Park JW; Koh DW; Lee WJ; Kim CM
Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
[TBL] [Abstract][Full Text] [Related]
37. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
[TBL] [Abstract][Full Text] [Related]
39. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.
Xu B; Lin L; Xu G; Zhuang Y; Guo Q; Liu Y; Wang H; Zhou X; Wu S; Bao S; Cai W; Xie Q
J Gastroenterol Hepatol; 2015 Feb; 30(2):372-8. PubMed ID: 25167956
[TBL] [Abstract][Full Text] [Related]
40. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
Wang JC; He LL; Chen Q
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
